hemophilianewstoday3d
FDA approves Alhemo for hemophilia A or B with inhibitors
The U.S. FDA has approved Alhemo, given as once-daily injections, to help prevent bleeds in patients with hemophilia A or B ...
Managed Healthcare Executive14d
Alhemo Once-Daily Treatment for Hemophilia A, B with Inhibitors FDA Approved
The FDA recently approved the treatment by Novo Nordisk for hemophilia A or B with inhibitors, designed to prevent or reduce ...
Zacks.com on MSN13d
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer ... recommending the approval of Alhemo (concizumab) for ...
BioWorld14d
Novo’s injectable hemophilia treatment approved by FDA
With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...
Novo Nordisk seeks to block compounded Victoza
Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...
Hosted on MSN20d
Novo Nordisk invests $1.2bn in new Denmark facility
Denmark-based pharma giant Novo Nordisk has announced plans to invest ... The company’s haemophilia portfolio includes Alhemo (concizumab) and its antibody asset Mim8, with the Phase III ...
Nasdaq13d
Novo Nordisk Stock Plunges 18% in a Week: What Should Investors Do?
recommending the approval of Alhemo (concizumab) for haemophilia A or B with inhibitors. A final decision is expected soon. Alhemo is not approved in the United States. Novo Nordisk is trading ...